Equities

Inspecs Group PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Inspecs Group PLC

Actions
Consumer DiscretionaryPersonal Goods
  • Price (GBX)75.00
  • Today's Change5.00 / 7.14%
  • Shares traded1.30m
  • 1 Year change+64.84%
  • Beta3.0187
Data delayed at least 20 minutes, as of Feb 09 2026 15:07 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

INSPECS Group plc is a United Kingdom-based provider of eyewear solutions for the global eyewear market. The Company produces a range of eyewear frames, low vision aids and lenses, covering optical, sunglasses and safety, which are either under license or under the Company’s own proprietary brands (Branded), or unbranded or private label on behalf of retail customers (OEM). The Company’s segments include Frames and Optics, which is involved in product distribution; and Manufacturing segment, which is engaged in OEM and manufacturing distribution. The Company has operations in the United Kingdom, Europe, the United States and China, including Hong Kong, Macau and Shenzhen, and manufacturing facilities in Vietnam, China, the United Kingdom and Italy. Its customers are global optical and non-optical retailers, global distributors and independent opticians, with its distribution network covering over 80 countries and reaching approximately 75,000 points of sale.

  • Revenue in GBP (TTM)192.83m
  • Net income in GBP-3.31m
  • Incorporated2019
  • Employees1.65k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Abingdon Health PLC8.43m-3.42m15.06m121.00--2.19--1.79-0.0176-0.01760.04350.02741.179.713.8769,661.16-47.42-54.04-70.70-85.9144.3230.37-40.51-110.071.58--0.1625--37.399.99-168.69---26.92--
Inspiration Healthcare Group PLC45.20m-11.44m15.24m214.00--0.9312--0.3372-0.1275-0.12750.50380.18261.032.005.91211,215.00-25.96-6.05-33.03-7.4544.3946.62-25.32-7.011.112.420.441--1.6516.56-148.04--39.05--
Aptamer Group PLC1.20m-2.42m24.95m31.00--13.33--20.74-0.0014-0.00140.00070.00070.42946.274.3538,806.45-86.53---154.00--48.13---201.50--1.48-84.630.2622--39.88--18.05------
Renalytix PLC2.20m-14.99m25.19m45.00------11.43-0.0597-0.05970.008-0.01550.45477.644.54---309.18-83.70---107.2540.0028.27-680.00-1,519.311.17-24.576.38--31.06--55.14------
Aoti Inc46.93m1.73m44.40m80.0021.063.4012.870.9460.01980.01980.47150.12261.322.174.65--4.87--6.54--88.13--3.69--2.542.810.5269--32.88--78.55------
Ondine Biomedical Inc1.18m-12.84m46.47m43.00--101.93--39.27-0.0352-0.03520.00320.00090.34470.57718.03---373.83---4,807.85--65.77---1,084.66--0.7948--0.4333--70.32---32.51------
Inspecs Group PLC192.83m-3.31m71.17m1.65k--0.79887.620.3691-0.0326-0.08061.900.87640.91382.317.71116,586.50-1.57-2.16-2.31-3.1351.8649.60-1.72-2.790.88471.730.3969---2.4832.80-362.19--4.97--
Creo Medical Group PLC2.20m12.60m73.21m133.006.001.205.2733.280.02960.02720.00560.14770.0319-0.80340.330816,541.3518.25-29.2520.62-35.8945.4547.22572.73-176.824.75-69.500.0645--0.00212.28-17.30---18.58--
SDI Group PLC69.29m4.59m85.75m504.0019.071.679.461.240.0430.0430.64970.49230.7692--5.78137,484.105.127.085.818.87--63.936.658.601.195.750.33630.000.502721.99-5.848.9911.55--
EKF Diagnostics Holdings PLC50.22m6.12m107.99m297.0018.521.579.832.150.01350.01350.11090.15970.62093.167.34165,745.907.985.798.776.7649.7949.4212.868.623.47--0.0152---4.592.25165.3911.163.02--
Tristel Plc46.46m6.64m204.56m265.0030.916.1821.674.400.13830.13830.96760.69151.041.935.81175,328.3014.859.6017.5711.0980.6280.9014.2911.042.96--0.1512120.7110.807.962.335.42-3.5918.10
Data as of Feb 09 2026. Currency figures normalised to Inspecs Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

51.34%Per cent of shares held by top holders
HolderShares% Held
Canaccord Genuity Wealth Ltd.as of 23 Oct 202515.34m15.09%
Downing LLPas of 03 Feb 20269.08m8.93%
Liontrust Investment Partners LLPas of 28 Nov 20258.38m8.24%
Royal London Asset Management Ltd.as of 31 Dec 20244.47m4.40%
Stonehage Fleming SAas of 31 Dec 20244.27m4.20%
Hargreaves Lansdown Fund Managers Ltd.as of 31 Dec 20243.56m3.50%
River Global Investors LLPas of 31 Dec 20253.54m3.48%
Oberon Investments Ltd. (GB Investment Management)as of 30 Sep 20251.94m1.91%
Stonehage Fleming Investment Management Ltd.as of 30 Sep 20251.61m1.58%
Skerryvore Asset Management Ltd.as of 31 Mar 20230.000.00%
More ▼
Data from 31 Dec 2024 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.